Jul 1, 2019
Immunology Market summarized details by key players are AbbVie, The Janssen Pharmaceutical Companies of Johnson & Johnson, F. Hoffmann-La Roche Ltd , F. Hoffmann-La Roche Ltd, Amgen, Pfizer, Novartis, Astellas Pharma US, Bristol-Myers Squibb and more

Pune, India - July 1, 2019 /MarketersMedia/ —
The Global Immunology Market is likely to expand in the coming years driven by the high prevalence of immunological disorders, resulting from environmental factors. According to a report published by Fortune Business Insights, titled “IMMUNOLOGY: GLOBAL MARKET ANALYSIS, INSIGHTS AND FORECAST, 2019-2026,” the market was valued at US$ 77,365.4 Mn in 2018. Fortune Business Insights has predicted that the market will reach US$ 143,833.2 Mn by 2026 and will exhibit a CAGR of 8.1%.
Sample PDF Brochure at https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/immunology-market-100657
Some of the major companies that are present in the Global Immunology Market are;
• AbbVie
• The Janssen Pharmaceutical Companies of Johnson & Johnson
• F. Hoffmann-La Roche Ltd
• Amgen
• Pfizer
• Novartis
• Astellas Pharma US
• Bristol-Myers Squibb
• Merck Animal Health
• UCB SA
• Allergan
• Other Prominent Players
The global immunology market is likely to expand in the coming years driven by the high demand for immunology drugs resulting from the high prevalence of immunological disorders. The severity of immunological disorders has created an increasing awareness around the world. Various initiatives and advisory programs have been conducted by the government as well as public organizations. This, in turn, will fuel the demand for immunology drugs. Furthermore, the increased efficiency of immunology drugs has contributed to better patient outcomes, which in turn has led to the subsequent growth of the global immunology market.
Recent Product Approvals by Regulatory Agencies to Bode Well for the Overall Market
The spate of recent regulatory approvals for the immunology products is anticipated to contribute to the overall positive growth of the market. For instance, the recent regulatory approval and the subsequent launch of TREMFYA (Guselkumab) by Janssen Global Services, LLC (Johnson & Johnson), is expected to lead to a better outcome for the patients. TREMFYA (Guselkumab) was launched for the treatment of moderate to severe plaque psoriasis, a seriously debilitating immunological disorder. TREMFYA is the only biologic approved for the treatment of moderate to severe plaque psoriasis, that selectively blocks the interleukin (IL)-23, leading to a vast improvement in the symptoms of the patient. Apart from being one of the emerging drugs of the immunology market, Fortune Business Insights predicts that Janssen Global Services, LLC (Johnson & Johnson) latest product offering will have a positive impact on the global immunology market in the forthcoming years
AbbVie Gains FDA Approval of SKYRIZI; Product to Witness High Demand in No Time
The global immunology market has gained impetus from the availability of several regulatory approved drugs. The approval of new drugs and the trends of improvements in clinical efficiencies will bode well for the global immunology market. In 2019, AbbVie received approval from the Food and Drug Administration (FDA) for the usage of ‘SKYRIZI’. The drug was aimed at the treatment of moderate to severe plaque psoriasis. This drug was inclined towards the treatment of adults diagnosed with psoriasis and have been recommended for or undergoing therapy. The drug is likely to gain huge popularity among healthcare professionals and its high clinical efficacy will fuel the demand in the coming years.
Besides product launches and drug approvals, Fortune Business Insights assesses several other factors that have made significant growth contributions to the global immunology market. Companies are encouraged by the growing usage approvals by regulatory authorities across the world. Several company mergers and acquisitions have also accounted for the growth of the global immunology market. Some of the leading companies that are operating in the global immunology market are AbbVie Inc., Janssen Global Services, LLC (Johnson & Johnson), F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc, Novartis AG, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, and ALLERGAN.
Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/immunology-market-100657
About Us:
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Info:
Name: Fortune Business Insights
Email: Send Email
Organization: Fortune Business Insights
Address: Fortune Business Insights Pvt. Ltd., 308, Supreme Headquarters,, Survey No. 36, Baner,, Pune-Bangalore Highway,, Pune - 411045, Maharashtra, India.
Phone: 4242530390
Website: https://www.fortunebusinessinsights.com/industry-reports/immunology-market-100657
Source: MarketersMedia
Release ID: 88891336
EXCLUSIVE: Netflix has ordered a second season of Polish drama Anaesthesia (Znieczulenie). The medical drama was a hit for the streamer, hitting the Top 10 list in Poland almost immediately after it launched and remaining there to this day, and is also fifth on Netflix’s global chart. Little surprise Season 2 has been greenlit in […]
Disney says it expects cash content spending of about $26 billion in fiscal 2027, up 9% from fiscal 2026. The projection was included in the company’s fiscal fourth-quarter earnings report Tuesday. Disney blew past Wall Street estimates in the quarter, posting strong results across its film and TV operations, streaming division and theme parks. The […]
German production company Schiwago has boarded adventure film “Southwest” by Ika Künzel and Wolfgang Fischer. The duo is also behind “Styx.” Set to be shoot in Namibia, it will star Avi Nash (“Silo,” “The Walking Dead”) and Antoine Reinartz (“Anatomy of a Fall,” “120 BPM”). Schiwago Film will also produce “Anatol” by Lukas Nathrath, his […]
Marvel viewership on Disney+ in the fourth quarter alone more than doubled compared to its historical baseline, according to the company's latest earnings report The post Disney Says Over 2.6 Billion Hours of Marvel Studios Content Was Streamed in Fiscal 2026 appeared first on TheWrap.
James Blunt follows through on name-change pledge after 'Airplane Mode' tops chartsJames Blunt appears to have followed through on a bizarre promise after his new album hit number one.The singer had said he would legally change his name to Ryan Air if Airplane Mode topped the UK charts. Once it...
Disney’s years-long effort to unify the Disney+ and Hulu apps is “nearly complete,” Mouse House execs said, as the company looks to concentrate its streaming firepower on the Disney+ platform. The company made the announcement in reporting earnings for the September 2026 quarter. Beginning this December, Disney+ and Hulu bundle subscribers “will have a fully […]
Disney had a robust quarter, topping Wall Street expectations on the top and bottom lines. But CEO Josh D’Amaro, who’s been in the job for eight months, sees an opportunity for the company to become even more efficient and help fuel future growth. For the three months ended Oct. 3, 2026, which is Disney’s fourth […]
Disney’s studio, streaming operation and theme parks all posted stellar results in the company’s fiscal fourth quarter, handily beating Wall Street forecasts. Total revenue surged 16% over the year-earlier period, hitting $25.95 billion. Earnings per share excluding certain items shot up to $1.77 from $1.11 a year ago. Analysts had been expecting revenue of $25.16 […]
“The least they could do,” Sir Christopher Hampton said about Glenn Close’s Honorary Oscar at the Tallinn Film Festival where at a masterclass, “From Stage to Screen, The Art of Adaptation,” the two-time Oscar winner delivered sometimes trenchant takes on AI – ‘I’m more interested in real intelligence’ – and how screenwriting was like gambling […]
Another day, another European microdrama contender. France-based vertical video drama app Storyshort has opened up a €1M ($1.1M) funding round “to accelerate across the French-speaking world.” Independent French M&A and corporate finance advisory firm VIFCO is supporting the action. Storyshort says it has produced 54 original series and gained more than 90 million views from […]
High scorers automatically qualify for a senior citizen discount. View Entire Post ›
Now that Robert Pattinson has been revealed as the next James Bond, all eyes are on who will be cast as 007’s arch nemesis — and Brad Pitt is putting himself up for the job. At the premiere of his new film “The Further Mis-Adventures of Cliff Booth” on Monday night, the Oscar winner reacted […]
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.